On Thursday, Piper Jaffray analysts raised the price target on shares of Chimerix Inc (NASDAQ: CMRX) to $37 from $33 and maintained an Overweight rating.
In light of the current Ebola concerns, Piper Jaffray analysts believe that Chimerix is the top Ebola play.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Joshua Schimmer finds that “Chimerix’s drug Brincidofovir is “an “attractive option” for government stockpiling, not only as potential treatment for Ebola but also for smallpox.”
Moreover, analysts noted, “A drug needs to show activity in two animal species, human safety to qualify for stockpiling; CMRX may be able to satisfy safety requirement with CMV program.”
Shares of Chimerix recently traded at $29.25, up 0.45 percent.
Crypto Whales Are Loading Up — Are You?
New research shows the biggest crypto buyers are back. And this time? They could hold for the possibility that Bitcoin will surpass $100,000 in 2024. You don’t want to miss the next massive crypto bull run like we saw in 2020 and 2021. To know exactly what’s going on and what to buy… Get Access To Benzinga’s Best Crypto Research and Investments For Only $1.